Life Science Partner places pharma and business development veteran to champion commercialization at Birmingham’s nationally-acclaimed research center.

Life Science Partner announces the placement of William S. “Sandy” White as chief executive officer at the UAB Research Foundation at the University of Alabama at Birmingham (UAB). White will guide patenting, commercializing and licensing efforts for products and technologies developed by UAB and Southern Research Institute faculty and staff.

The UAB Research Foundation, established in 1987, identifies, assesses, protects, and markets intellectual property developed at the nationally-renowned UAB medical research center and at Southern Research, an affiliated not-for-profit drug discovery and technology development organization.

“Sandy has extraordinary experience in both the commercialization of technology from the pharmaceutical industry and in regional, high-tech development,” says Life Science Partner Founder and President Thomas H. Callaway. “This unique combination of entrepreneurial talents suits him well for the partnering work and economic outreach he’ll be asked to undertake as a champion of the biosciences community in Alabama.”

An accomplished biotech corporate leader and MBA with degrees in pharmacy and biology, White moves to UAB from his role as president and CEO at the Columbus Technology Council. At this non-profit organization that fosters growth in central Ohio’s high technology sector, White oversaw ongoing operations, an organizational merger, and the development and adoption of overall technology commercialization plan including venture capital, incubators, research parks and basic academic research.

As an independent consultant, White provided business development and management consulting services. He also served the University of Georgia’s first Venture Fellow, assisting and promoting the development of early-stage companies at the University.

White also previously served as president, CEO and director at BioCache Pharmaceuticals, an early-stage biotechnology company focused on development and commercialization, as it sought to grow from an academic setting with a basic research approach into a commercially driven entity.

Until shortly after the Monsanto-Pharmacia merger, White was president and business leader for Integrated Protein Technologies, a unit responsible for creating and developing new pharmaceutical-based businesses within the corporation. White held responsibility over the technical and commercial evaluation of business opportunities in the earliest stages of development for this enterprise held up as exemplary in Monsanto’s efforts to advance global healthcare.

While vice president of commercial development and planning for pharmaceutical R&D at the Storz Ophthalmics division of American Home Products Company, White managed development and marketing research for both pharmaceuticals and devices at this $250 million organization.

White was director of business development at a Boehringer Ingelheim subsidiary, Clinical Research Foundation, a clinical research organization for which he developed the initial business plan. At Adria Laboratories, a pharmaceutical company focused primarily on oncology, he served as manager of new business development and licensing. White began his career as a manager of regulatory affairs and, later, new product planning at A.H. Robins.

White holds a bachelor’s in biology from the University of Virginia and a bachelor’s in pharmacy from the Medical College of Virginia. He earned an MBA from Virginia Commonwealth University.

Life Science Partner’s high-quality executive and scientific recruiting services target the very specific needs of life sciences and healthcare organizations. We identify and recruit the brightest talent in the biotechnology, pharmaceutical, medical device and healthcare services fields.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

To build Serologicals’ product portfolio, Life Science Partner recruits former Amersham Biotech head of North American R&D, global genomics.

Life Science Partner announces the placement of Dennis W. Harris as vice president of research and development/business development and chief scientific officer at Serologicals Corporation in Norcross, Georgia.

With the move, Harris becomes the senior leader in strategic planning for overall product portfolio expansion as well as identification and development of new product opportunities. Serologicals is a global provider of products and technologies for the development and manufacture of biologically based products. The company competes in three primary areas: specialty cell culture supplements, life science reagents, and diagnostic antibodies.

“In Harris, Serologicals welcomes just the right talent for their product development efforts,” says Life Science Partner Founder and President Thomas H. Callaway. “Harris is a leader in creating integrated systems for genomics and the discovery sciences. And he’s a proven R&D manager at the global level as well.”

Throughout his 22-year career, Harris has demonstrated both a keen scientific awareness and an aptitude for successfully managing research and development projects in the molecular biology industry. In his dual role as vice president of research and development for North America and genomics at Amersham Pharmacia Biotech, for example, Harris led an organization with 220 scientists and engineers while maintaining strategic responsibility for genomics research worldwide, among other duties.

Harris comes to Serologicals most recently from Vitra Bioscience, where he served as executive vice president of research and development. At Vitra, Harris held primary responsibility for automating and integrating cellular assays with engineering software for higher throughput as well as cultivating relationships with top pharmaceutical companies.

As senior vice president for ACLARA BioSciences, a developer of technologies for gene and protein analysis, he directed the company’s R&D program and was heavily involved in strategic development. Later, Harris led system integration and business development efforts at ACLARA BioSciences, in which capacity he closed the company’s largest deal.

Harris launched his career as a development scientist with Amersham in 1982. As life sciences research program manager, based in England, he later led a team of scientists funded by the European Economic Community to develop automated systems for DNA sequencing, template preparation and related methodologies. More recently, while senior program manager at Molecular Dynamics (later acquired by Amersham), he directed the development and launch of the MegaBACE 1000 DNA Sequencing System. In this role, he provided technical and strategic direction while managing engineering, software, applications, reagent development, and marketing. He was then promoted to vice president of research and development for North America and genomics, a position he held for three years.

Harris holds a doctorate in biochemistry from the University of Sussex, Brighton, UK.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits pharma finance executive with entrepreneurial and global R&D experience

Life Science Partner announces the placement of James A. Klein, Jr., as chief financial officer at Adherex Technologies, Inc., to be based in its new Research Triangle Park, North Carolina headquarters. Klein assumes overall responsibility for the company’s financial health and integrity. He will oversee ongoing financing of this publicly traded company, including analysis and review of financial data, reporting performance, and internal operations.

A biopharmaceutical company, Adherex discovers and develops cancer therapeutics through its pioneering platform for tumor vascular targeting.

“James Klein’s broad, varied experience prepares him well for Adherex,” says Life Science Partner Founder and President Thomas H. Callaway. “On the one hand, he directed finance for a $500 million international research operation at Wellcome. On the other hand, he was the start-up CFO of an emerging pharma company. So he’s a proven quantity and a tremendous resource.”

To his experience in finance matters ranging from intellectual property to IPOs to cost controls, Klein adds a firm understanding of the drug development, research organizations, and business management. Klein transitions to Adherex from a company he founded, DataScout Software, which develops data acquisition and management solutions for the pharmaceutical industry.

Previously, Klein was an early employee of Triangle Pharmaceuticals, serving as CFO and treasurer. With Klein managing all financial aspects of the operation, Triangle raised venture capital and held a successful initial public offering.  With a market capitalization of more than $500 million at Triangle, Klein oversaw SEC filings, financial reporting, accounting, budgeting, long-range planning, risk management, as well as investor relations.

At Burroughs, Klein held the titles of international R&D financial controller, senior financial analyst, and various other corporate accounting positions. Here, he held financial responsibility for a $500 million, international R&D operation. In addition to financial reporting, Klein guided business plans for new product acquisitions; managed facilities expansions; and served as a member of the international integration committee during the Glaxo-Wellcome merger.

Klein earned his accounting degree at the University of Mississippi. He is a certified public accountant in the state of North Carolina.

Life Science Partner places sales and marketing veteran to guide U.S.-based operations and commercialization for innovative medical device firm.

Life Science Partner announces the placement of Patrick A. Maley as president, North America for Itamar Medical, Ltd. In this capacity, Maley assumes overall responsibility for U.S.-based operations. He will establish the company’s commercialization strategy; build a sales and marketing team; lead pharmaceutical, medical and other partnering efforts; and represent the company to financial institutions, the medical community and the media.

Israel-based Itamar has developed a technology, the peripheral arterial tone signal or PAT. Among other applications, PAT improves diagnoses of disorders related to arterial health, such as sleep apnea.

“Patrick has a distinguished, decades-long record of bringing novel products to market for both established medical device companies and start-ups,” says Thomas H. Callaway, Life Science Partner’s founder and president. “And his ability to apply creative marketing and reimbursement strategies has yielded commercial results for innovative technologies.”

From re-thinking product distribution channels to building high-performance sales and marketing divisions to negotiating multi-million-dollar global partnerships, Maley’s efforts have repeatedly contributed to steady revenue growth. Maley comes to Itamar from the chief operating officer position at Biowave, where he led organizational development and go-to-market strategy for an innovative pain therapy product.

As vice president of sales and marketing – business development at Matritech, Maley held worldwide commercialization responsibilities for bladder, cervical, prostate, breast and colon cancer products. For Zoll Medical, as vice president of sales and marketing, Maley managed global marketing and North American sales, with profit-and-loss responsibility for a 110-person team. While at Zoll, he re-positioned product lines, re-organized the sales force according to target market, and better integrated sales, marketing and R&D.

Maley also held vice president titles and led global sales and marketing teams at Boston Scientific’s Mansfield Cardiology Division, medical device start-up company ASI, and Alcon Surgical.

Maley earned both a bachelor’s degree in economics and an MBA from the University of California, Riverside.

Life Science Partner places business-savvy surgeon to manage promising new interventional spine therapy division.

Life Science Partner announces the placement of Gregory J. Vaughn, MD, as general manager of the new interventional spine business unit, at Medtronic Sofamor Danek, a subsidiary of Medtronic.

In his new role for the early-stage spinal therapy division, Dr. Vaughn assumes leadership over strategic planning, technology and competitive assessment, operations, research and development, sales and marketing, and finance. Medtronic Sofamor Danek develops and manufactures a variety of products for use in treating spinal and cranial disorders.


“Greg’s accomplishments make him an excellent choice to grow this high-potential division within a well established medical products company,” says Thomas H. Callaway, Life Science Partner’s founder and president. “His clinical knowledge as a surgeon and his experience in organizational performance will help him lead this division in pursuing
innovative therapies for spinal health and reconstruction.”


With Dr. Vaughn’s arrival at one of Medtronic Sofamor Danek’s key new business units, the company gains an informed, strategic thinker with exceptional collaborative and organizational talents. And Dr. Vaughn’s experience as a maxillofacial and ophthalmic surgeon lends him a deeper understanding of the medical community’s concerns.


Dr. Vaughn comes to Medtronic Sofamor Danek from NDCHealth, where, as vice president and general manager for the company’s point-of-service pharmacy information systems division, he oversaw a $100-million-revenue business and more than 200 managers in four locations. He was originally recruited to NDCHealth as vice president of strategy and planning. In that capacity, he guided the chief executive and the board through the development of a five-year corporate plan.


With McKinsey & Company as engagement manager, he led a range of cross-industry business consulting projects for clients such as Wake Forest University, Duke University, Skanska and CIBA Vision/Novartis. His assignments included organizational efficiency improvement at Wake’s technology transfer office, supply chain cost reduction for Duke, talent identification and retention for Skanska, and strategic integration plans for CIBA Vision.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner placement brings a broad portfolio of business management and leadership skills to outpatient rehabilitation division

Life Science Partner announces the placement of Diane L. Munson as president of the outpatient rehabilitation division at Birmingham-based HealthSouth. In this role, Munson will lead a team of senior executives that oversees a 6,700-employee division with approximately 1,000 facilities and $620 million in revenue. Munson will direct the group’s senior leadership; guide strategic planning; strengthen operations, sales and marketing; and maintain general business practices and financial standards.

HealthSouth is the nation’s largest provider of rehabilitative health care and outpatient surgery services with nearly 1,700 facilities worldwide and projected 2004 revenues of $4.3 billion.

“Two of the common threads throughout Diane’s career have been team-building and integrity,” says Life Science Partner Founder and President Thomas H. Callaway. “She’s been able to assemble the people and resources necessary to grow into new markets profitably or bring underperforming organizations back to life. And she has cultivated a management style as a straightforward communicator who finds ways to inspire. These will be valuable tools in running an organization with the scale and prestige of HealthSouth’s rehabilitation business.”

Munson brings to HealthSouth the financial perspective of an organizational leader and the clinical background of a former nurse. Her varied accomplishments in diverse healthcare fields span management strategy, new business development, corporate turnaround projects, quality programs and more.

Munson comes to HealthSouth from Beverly Enterprises, an eldercare and rehabilitation services provider with $2 billion in revenues. At Beverly, she led the corporate quality and clinical management program as senior vice president of professional services. She also managed the successful turnaround and sale of a homecare subsidiary as its vice president and general manager.

Munson has served as president and CEO of Fluidsense, an IV infusion pump and software company. And as senior vice president of healthcare services for Inlight, an e-health company focused on prescriptive patient education and healthcare resource management, she directed national sales, sales operations and product launch initiatives.

With Caremark International, Munson held several titles. While corporate vice president for physician services, she was a member of the senior management team and held profit-and-loss responsibility for the physician practice business’ 15,000 employees and $1 billion budget. Munson grew the business aggressively through acquisition and expansion, increasing revenues from $130 million to $1 billion in three years—while reducing operating costs by $40 million. Munson was also president of Caremark Homecare, whose more than 1,000 employees provided intravenous treatment and services for patients with AIDS, cancer, kidney disease or digestive disorders.

After a 12-year career at Baxter International, Munson left the company as president of the general healthcare division. While president, Munson introduced alternate site sales and distribution strategies to reach $120 million in sales across the physician, long-term care, homecare and veterinary markets. During this time, the group reversed a negative sales trend to post double-digit profitability growth.

Munson has an undergraduate degree from Northwestern University and an associate’s nursing degree from Prairie State College.

Life Science Partner’s high-quality executive and scientific recruiting services target the very specific needs of life sciences and healthcare organizations. We identify and recruit the brightest talent in the biotechnology, pharmaceutical, medical device and healthcare services fields.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner connects experienced medical product engineer with radiation delivery systems company:

Life Science Partner announces the placement of R. Michael Webster as senior director of product development at Proxima Therapeutics in Alpharetta, Georgia. In this new capacity, Webster assumes overall responsibility for the development and improvement of products based upon the company’s proprietary delivery system. He will oversee a team of engineers as well as external engineering and manufacturing resources. Proxima Therapeutics, a privately held medical device company, develops innovative radiation delivery systems for the treatment of solid cancerous tumors.

“Michael is regarded by his peers—and the engineers who have served on his teams—as an excellent manager,” says Life Science Partner Vice President Cynthia B. Roberts. “With his start-to-finish engineering expertise from design and development through manufacturing, he’ll prove a strong asset for Proxima.”

Webster is an accomplished project manager with a 17-year career spent engineering balloon and other catheters as well as radiation therapy products. Prior to joining Proxima, Webster was group manager, research and development at Novoste Corporation in Norcross, Georgia. At Novoste, Webster guided strategy, scheduling, budgeting, product development conformity, quality protocols and regulatory efforts.

As program manager with the Balloon Catheter/Stent Delivery Systems Group at Cordis Corporation in Miami Lakes, Florida, Webster led engineering activities on multiple PTCA/PTA delivery system projects. His responsibilities included physician opinion evaluation, product design, competitive product analysis, and portfolio strategies.

Webster initiated his medical device career at North American Instrument Corporation (NAMIC), Glens Falls, New York, where he was senior manufacturing engineer in the project engineering department. With NAMIC, he was task team leader for new product and automation projects including an inflation device for cardiology, radiology drainage bag manufacturing, an introducer sheath, and many more.

During a combined seven years at Coleco Industries and Ingersoll-Rand, Webster also worked as an engineer focused on consumer products and power tools manufacturing.

About Life Science Partner Executive Search

Life Science Partner’s high-quality executive and scientific recruiting services target the very specific needs of life sciences and healthcare organizations. We identify and recruit the brightest talent in the biotechnology, pharmaceutical, medical device and healthcare services fields.

Life Science Partner placement offers valuable experience in technology and commercialization assessment

Life Science Partner announces the placement of Lothar Krinke, PhD, as senior director of biosciences technology development for Minneapolis-based Medtronic, Inc. In this new role, Krinke will lead new technology assessment efforts and manage relationships with key external partner institutions. Krinke will also collaborate with Medtronic’s regulatory, clinical and marketing teams to analyze business opportunities in biotechnology and gauge the feasibility of related research programs.

Krinke comes to Medtronic with 13 years of experience in evaluating new medical technologies and lines of business. As a consultant and, more recently, with early stage biotechnology firms, he has demonstrated his ability to assess complex technologies for their commercial potential.

Medtronic, a leading medical technology company, has more than $7 billion in annual revenues.

“With Lothar, Medtronic is gaining a rare combination of applied experience, broad collaboration with companies in the life sciences, and a consultant’s systematic approach to recommending action,” says Life Science Partner Vice President Cynthia B. Roberts. “He will prove a valuable addition to Medtronic’s biotechnology team.”

Prior to Medtronic, Krinke helped found Endogeny Bio Corp. and served as its vice president of business development. He held responsibility for licensing, contracting, intellectual property development and business planning.

Krinke also founded a consulting firm, Biostrategic Solutions, which offers strategic analysis and planning services to biotechnology, pharmaceutical and medical products companies.

At Celera Genomics previously, Krinke was vice president and chief business officer of Celera Online, in which capacity he led the commercial operations of the company’s information business, including marketing, proposals and contracts, client programs, bioinformatics solutions and product strategy. In an earlier position at Celera Genomics, as vice president of business development and strategic planning, Krinke was responsible for strategy, mergers and acquisitions, and licensing. He identified and successfully acquired Axys Pharmaceuticals at that time.

Over ten years as a consultant with McKinsey & Company and, later, A.T. Kearney, Krinke served biopharmaceutical, genomics, medical products and other life sciences companies. His work involved technical assessment and financial valuation, licensing strategy, e-business strategy, corporate transactions and post-merger integration planning, and R&D and commercialization strategy.

Krinke was an American Cancer Society Postdoctoral Research Fellow and a Procter & Gamble Postdoctoral Fellow at the California Institute of Technology. He earned his doctorate in molecular biology at the University at Albany, State University of New York. He holds an undergraduate degree in biology from Technische Universität Braunschweig in Germany.

Life Science Partner recruit an accomplished communicator, crisis manager and media expert

Life Science Partner announces the placement of Jeanne Forbis as vice president, public and media relations for Minneapolis-based Medtronic, Inc. Forbis will hold worldwide responsibility for public and media relations, community affairs, brand management and the Medtronic Foundation.

An award-winning communications expert with 24 years of experience, Forbis will also lead corporate communications strategy and represent the company as a spokesperson. Medtronic, a leading medical technology company, has more than $7 billion in annual revenues.

“As a former journalist, spokesperson and media relations executive, Jeanne clearly possesses the depth of experience and breadth of skills to have an impact at Medtronic,” says Life Science Partner Founder and President Thomas H. Callaway. “The placement is particularly noteworthy, however, because Jeanne was drawn not only to the opportunity, but to Medtronic’s mission.”

Over her career, Forbis has held leadership roles at major newspapers, guided relations with the financial and lay press, managed crisis response and advised on senior executive communication strategies. Prior to Medtronic, she was general manager, corporate communications at ChevronTexaco, the second largest American energy company.

As manager, corporate communications at Conoco, Forbis guided executive, financial and employee communications through major transitions such as the company’s merger with Phillips Petroleum, Conoco’s split from DuPont and initial public offering, and the acquisition of Gulf Canada.

In managing the Conoco-Phillips merger while at Conoco, Forbis leveraged her previous seven years of experience at Phillips Petroleum, where she served as a company spokesperson in media relations and as financial communications coordinator.

Between 1979 and 1990, Forbis held editorial titles at Tulsa World and The St. Louis Sun.

Forbis holds a bachelor’s degree in mass communications from Oklahoma State University.

Life Science Partner placement brings a record of innovation to Atlanta-based company

Life Science Partner announces the placement of Dr. David J. Enscore as senior vice president, product research and development with Altea Therapeutics in Atlanta. As an integral part of Altea’s executive leadership, the 20-year industry veteran will direct pharmaceutical and clinical product development while playing an important role in identifying and pursuing strategy. Altea Therapeutics works with the pharmaceutical and biotechnology industries to develop alternatives for medicine and vaccine delivery.

“When we introduced David to Altea, he was very impressed with the company and its microporation technology,” says Life Science Partner Founder and President Thomas H. Callaway. “Because there are so few candidates with David’s qualifications and his unique background suits Altea’s needs perfectly, this is an exceptional placement.”

Enscore comes from Spherics, a Rhode Island-based early phase drug delivery company using bioadhesive polymers and nanoencapsulation to improve the oral bioavailability of therapeutic agents. As vice president of R&D there, he was responsible for all scientific and technical operations the from the company’s inception. Later, Enscore assumed general management responsibilities as well. With Focal, Inc., a medical device company commercializing resorbable surgical sealants and drug delivery platform polymers, he served as vice president and guided all materials-related activities, including all research and development activities related to Focal’s core polymer technologies. During a 16-year career at ALZA Corporation, where he began his career as a chemical engineer, Enscore held the titles of executive director, transdermal product development; director, new product discovery; director, physical sciences; and others. At ALZA, he managed the development of four controlled release pharmaceuticals including the NicoDerm CQ patch. Enscore is an inventor on 24 U.S. patents in drug delivery and medical devices.

Enscore earned both his doctorate in chemical engineering (with a minor in polymer science) and his bachelor’s in chemical engineering at North Carolina State University.